Roche: starts cash tender offer for Ignyta shares
(CercleFinance.com) - Roche has kicked off its cash tender offer for all of the shares of US cancer diagnostics firm Ignyta, the Swiss drugmaker said on Wednesday.
The offer, which is at a price of 27 dollars per share, will expire at the end of business on 7 February - unless extended - the company said.
Following the offer's completion, any shares not acquired in the process will be acquired in a second step merger at the same price of 27 dollars per share, Roche said.
The transaction is expected to be closed in the first half of 2018.
Roche said in late December that it reached an agreement to buy Ignyta for 1.7 billion dollars to strengthen its oncology portfolio.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The offer, which is at a price of 27 dollars per share, will expire at the end of business on 7 February - unless extended - the company said.
Following the offer's completion, any shares not acquired in the process will be acquired in a second step merger at the same price of 27 dollars per share, Roche said.
The transaction is expected to be closed in the first half of 2018.
Roche said in late December that it reached an agreement to buy Ignyta for 1.7 billion dollars to strengthen its oncology portfolio.
Copyright (c) 2018 CercleFinance.com. All rights reserved.